Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726449 | 0.77 | ALDH1A1 (0.44) | ALDH1A1PYCR1KMT2AMEN1TSHR | |
| SCHEMBL979334 | 0.74 | DGAT1 (0.41) | ALDH1A1PYCR1KMT2ALMNACYP2A6 | |
| SCHEMBL31261561 | 0.72 | ALDH1A1 (0.41) | ALDH1A1PYCR1HSD11B1KMT2AMEN1 | |
| SCHEMBL21177435 | 0.72 | CCR5 (0.49) | ALDH1A1PYCR1KMT2AMEN1TSHR | |
| SCHEMBL415375 | 0.72 | ALDH1A1 (0.38) | ALDH1A1PYCR1NT5EHSD11B1KMT2A | |
| SCHEMBL21585255 | 0.70 | HRH4 (0.43) | NT5E | |
| SCHEMBL29405402 | 0.69 | — | — | |
| SCHEMBL125688 | 0.69 | — | — | |
| SCHEMBL23853796 | 0.69 | ALDH1A1 (0.38) | ALDH1A1NT5EHSD11B1KMT2AMEN1 | |
| SCHEMBL14758469 | 0.69 | LMNA (0.40) | ALDH1A1PYCR1KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248506-A | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | ALDH1A1 109/4885PYCR1 499/4885NT5E 1634/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | ALDH1A1 109/4885PYCR1 499/4885NT5E 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.